Venn Life Sciences Holdings PLC Directorate Change (6049J)

TIDMVENN

RNS Number : 6049J

Venn Life Sciences Holdings PLC

13 September 2016

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company" or the "Group")

Appointment of Chairman

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.

Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will benefit Venn.

Tony Richardson, Chief Executive Officer of Venn said: "I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan's experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders."

Mr. Wood has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM Rules and the ESM Rules.

 
 Current directorships         Directorships or partnerships 
  or partnerships               in the last five years 
 
 Oxehealth Limited             Trustmarque Solutions Limited 
 Ardvarna Investment Capital   Healthcare Homes Holdings 
  Limited                       Limited 
 Eclipse Film Partnership      HWH Plus Limited 
  No. 22 LLP 
 The Augusta Film Limited      HWH Group Limited 
  Liability Partnership 
                               WCI Group Trustee Company 
                                Limited 
                               Creare Franchise Limited 
                               Creare Communications (UK) 
                                Limited 
                               Creare Communications (Holdings) 
                                Limited 
                               Care UK (Urgent Care) Holdings 
                                Limited

Mr. Wood does not hold any ordinary shares in Venn Life Sciences.

 
  Venn Life Sciences Holdings            www.vennlifesciences.com 
   Plc 
  Tony Richardson, Chief Executive           Tel: +353 154 99 341 
   Officer 
 
  Davy (Nominated Adviser, ESM 
   Adviser and Joint Broker) 
  Fergal Meegan / Matthew de Vere            Tel: +353 1 679 6363 
   White (Corporate Finance) 
  Paul Burke (Corporate Broking) 
 
  Hybridan LLP (Co-Broker) 
  Claire Louise Noyce                     Tel: +44(0)20 3764 2341 
 
  Walbrook PR Ltd                      Tel: +44(0)20 7933 8787 or 
                                              venn@walbrookpr.com 
  Paul McManus                           Mob: +44(0) 7980 541 893

About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABUGDCUDBBGLD

(END) Dow Jones Newswires

September 13, 2016 02:01 ET (06:01 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024